BACKGROUND: Transcatheter tricuspid valve repair (TTVR) is a promising technique for the treatment of tricuspid regurgitation (TR). Data comparing the performance of novel edge-to-edge devices (PASCAL and MitraClip-XTR) are scarce. METHODS: We identified 80 consecutive patients who underwent TTVR using either the PASCAL or MitraClip-XTR system to treat symptomatic TR from July 2018 to June 2020. To adjust for baseline imbalances, we performed a propensity score (PS) 1:1 matching. The primary endpoint was a reduction in TR severity by at least one grade at 30 days. RESULTS: The PS-matched cohort (n = 44) was at high-surgical risk (EuroSCORE II: 7.5% [interquartile range (IQR) 4.8-12.1%]) with a mean TR grade of 4.3 ± 0.8 and median coaptation gap of 6.2 mm [IQR 3.2-9.1 mm]. The primary endpoint was similarly observed in both groups (PASCAL: 91% vs. MitraClip-XTR: 96%). Multiple device implantation was the most common form (59% vs. 82%, p = 0.19), and the occurrence of SLDA was comparable between the PASCAL and MitraClip-XTR system (5.7% [2 of 35 implanted devices] vs. 4.4% [2 of 45 implanted devices], p = 0.99). No periprocedural death or conversions to surgery occurred, and 30-day mortality (5.0% vs. 5.0%, log-rank p = 0.99) and 3-month mortality (10.0% vs. 5.0%, log-rank p = 0.56) were similar between both groups. During follow-up, functional NYHA class, 6-min walking distance, and health status improved in both groups. CONCLUSIONS: Both TTVR devices, PASCAL and MitraClip-XTR, appeared feasible and comparable for an effective TR reduction. Randomized head-to-head comparisons will help to further define the appropriate scope of application of each system.
BACKGROUND: Transcatheter tricuspid valve repair (TTVR) is a promising technique for the treatment of tricuspid regurgitation (TR). Data comparing the performance of novel edge-to-edge devices (PASCAL and MitraClip-XTR) are scarce. METHODS: We identified 80 consecutive patients who underwent TTVR using either the PASCAL or MitraClip-XTR system to treat symptomatic TR from July 2018 to June 2020. To adjust for baseline imbalances, we performed a propensity score (PS) 1:1 matching. The primary endpoint was a reduction in TR severity by at least one grade at 30 days. RESULTS: The PS-matched cohort (n = 44) was at high-surgical risk (EuroSCORE II: 7.5% [interquartile range (IQR) 4.8-12.1%]) with a mean TR grade of 4.3 ± 0.8 and median coaptation gap of 6.2 mm [IQR 3.2-9.1 mm]. The primary endpoint was similarly observed in both groups (PASCAL: 91% vs. MitraClip-XTR: 96%). Multiple device implantation was the most common form (59% vs. 82%, p = 0.19), and the occurrence of SLDA was comparable between the PASCAL and MitraClip-XTR system (5.7% [2 of 35 implanted devices] vs. 4.4% [2 of 45 implanted devices], p = 0.99). No periprocedural death or conversions to surgery occurred, and 30-day mortality (5.0% vs. 5.0%, log-rank p = 0.99) and 3-month mortality (10.0% vs. 5.0%, log-rank p = 0.56) were similar between both groups. During follow-up, functional NYHA class, 6-min walking distance, and health status improved in both groups. CONCLUSIONS: Both TTVR devices, PASCAL and MitraClip-XTR, appeared feasible and comparable for an effective TR reduction. Randomized head-to-head comparisons will help to further define the appropriate scope of application of each system.
Authors: Maurizio Taramasso; Hannes Alessandrini; Azeem Latib; Masahiko Asami; Adrian Attinger-Toller; Luigi Biasco; Daniel Braun; Eric Brochet; Kim A Connelly; Paolo Denti; Florian Deuschl; Andrea Englmeier; Neil Fam; Christian Frerker; Jörg Hausleiter; Dominique Himbert; Edwin C Ho; Jean-Michel Juliard; Ryan Kaple; Felix Kreidel; Karl-Heinz Kuck; Marco Ancona; Alexander Lauten; Philipp Lurz; Michael Mehr; Tamin Nazif; Georg Nickening; Giovanni Pedrazzini; Alberto Pozzoli; Fabien Praz; Rishi Puri; Josep Rodés-Cabau; Ulrich Schäfer; Joachim Schofer; Horst Sievert; Kolja Sievert; Gilbert H L Tang; Felix C Tanner; Alec Vahanian; John G Webb; Stephan Windecker; Ermela Yzeiray; Michel Zuber; Francesco Maisano; Martin B Leon; Rebecca T Hahn Journal: JACC Cardiovasc Interv Date: 2018-12-26 Impact factor: 11.195
Authors: Neil P Fam; Daniel Braun; Ralph Stephan von Bardeleben; Michael Nabauer; Tobias Ruf; Kim A Connelly; Edwin Ho; Holger Thiele; Philipp Lurz; Marcel Weber; Georg Nickenig; Akhil Narang; Charles J Davidson; Jörg Hausleiter Journal: JACC Cardiovasc Interv Date: 2019-12-23 Impact factor: 11.195
Authors: Suzanne V Arnold; Khaja M Chinnakondepalli; John A Spertus; Elizabeth A Magnuson; Suzanne J Baron; Saibal Kar; D Scott Lim; Jacob M Mishell; William T Abraham; JoAnn A Lindenfeld; Michael J Mack; Gregg W Stone; David J Cohen Journal: J Am Coll Cardiol Date: 2019-03-17 Impact factor: 24.094
Authors: Yan Topilsky; Vuyisile T Nkomo; Ori Vatury; Hector I Michelena; Thierry Letourneau; Rakesh M Suri; Sorin Pislaru; Soon Park; Douglas W Mahoney; Simon Biner; Maurice Enriquez-Sarano Journal: JACC Cardiovasc Imaging Date: 2014-11-05
Authors: Lluis Asmarats; Gidon Perlman; Fabien Praz; Mark Hensey; Michael P Chrissoheris; Francois Philippon; Hadass Ofek; Jian Ye; Rishi Puri; Philippe Pibarot; Adrian Attinger; Robert Moss; Elisabeth Bédard; Aris Moschovitis; David Reineke; Sandra Lauck; Philipp Blanke; Jonathon Leipsic; Konstantinos Spargias; Stephan Windecker; John G Webb; Josep Rodés-Cabau Journal: JACC Cardiovasc Interv Date: 2019-08-12 Impact factor: 11.195
Authors: Ciro Santoro; Alvaro Marco Del Castillo; Ariana González-Gómez; Juan Manuel Monteagudo; Rocio Hinojar; Alvaro Lorente; María Abellás; Jose Maria Vieitez; Ana Garcia Martìn; Eduardo Casas Rojo; Soledad Ruíz; Vivencio Barrios; Jose Luis Moya; Jose Julio Jimenez-Nacher; Jose Luis Zamorano Gomez; Covadonga Fernández-Golfín Journal: Eur Heart J Cardiovasc Imaging Date: 2019-09-01 Impact factor: 6.875
Authors: Anna Sannino; Federica Ilardi; Rebecca T Hahn; Patrizio Lancellotti; Philipp Lurz; Robert L Smith; Giovanni Esposito; Paul A Grayburn Journal: Front Cardiovasc Med Date: 2022-07-11
Authors: Jan A Krikken; Ad F M van den Heuvel; H Marco Willemsen; Adriaan A Voors; Erik Lipsic Journal: Neth Heart J Date: 2022-03-29 Impact factor: 2.854